ArticleClinical rheumatology2025
Identification of shared diagnostic biomarkers and potential co-morbidity mechanisms between primary Sjogren's syndrome and chronic kidney disease.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe mechanisms linking primary Sjogren's syndrome (pSS) to chronic kidney disease (CKD) are obscure. Our study sought to uncover shared genetic connections and pathways between these conditions.
methodsDatasets for pSS and CKD were sourced from GEO. WGCNA alongside differential expression assessment was employed to pinpoint common genes. GO and KEGG were applied for gene enrichment. Key genes were selected using LASSO, Random Forest, and SVM-RFE. Clinical prediction models were constructed using multi-factor logistic regression. GSEA and immune infiltration analyses explored the mechanisms linking key genes in pSS and CKD. MR analysis and SMR approach assessed the genetic link between pSS and CKD, evaluating the impact of co-shared genes on these conditions.
resultWe identified 104 common genes using WGCNA and differential expression analysis. GO and KEGG analyses hinted at cancer involvement in both diseases. Machine learning models pinpointed five genes as strong diagnostic biomarkers for both pSS and CKD, with NUDT1 and COMMD2 validated in independent cohorts. Clinical prediction models were constructed based on these two genes. GSEA and immune infiltration analysis suggested immune processes, particularly T cell infiltration, were implicated in both diseases. Bidirectional MR analysis failed to establish a causal link between the two diseases, yet SMR analysis revealed associations between NUDT1 and COMMD2 expression and the development of pSS and CKD.
conclusionThis study uncovered crucial genes shared between pSS and CKD, shedding light on their co-morbidity mechanisms and possible diagnostic biomarkers. Key Points • This study unveils for the first time the immunological association between PSS and CKD. • NUDT1 and COMMD2 are identified as key molecules in the comorbidity mechanism of PSS and CKD. • A diagnostic model for the comorbidity of PSS and CKD is constructed.
Indexed as
Identifiers
40957961What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.